Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurological biopharmaceuticals developer Renovis has completed enrollment of patients in its phase II trial of REN-1654 in the treatment of post-herpetic neuralgia, an often debilitating form of neuropathic pain that can follow shingles.
Subscribe to our email newsletter
The primary goal of this trial is to assess the safety and effectiveness of REN-1654 in treating acute pain in post-herpetic neuralgia (PHN) patients.
“We are pleased to have reached this milestone in the development of REN-1654 and look forward to reporting top line results from this trial before the end of the first quarter of 2005,” said Dr Randall Moreadith, chief medical officer of Renovis. “Enrollment is continuing in a second phase II trial with REN-1654 in patients suffering from sciatica. We expect to complete enrollment and analysis of that trial later this year.”
The phase II trial of REN-1654 in PHN patients is a randomized, double-blind, placebo-controlled trial that has enrolled more than 90 patients at multiple centers in the US. The effectiveness of REN-1654 will be assessed based on the change in pain levels and quality of life scores experienced by patients receiving REN-1654 compared to patients receiving placebo.